Marizomib(Synonyms: Salinosporamide A; NPI-0052)

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

Marizomib (Synonyms: Salinosporamide A; NPI-0052) 纯度: ≥98.0%

Marizomib (Salinosporamide A) 是第二代不可逆的脑渗透性泛蛋白酶体 (proteasome) 抑制剂。Marizomib 抑制 20S 蛋白酶体的 CT-L (β5)、CT-T-laspase 样 (C-L, β1) 和胰蛋白酶样 (T-L, β2) 活性 (IC50 分别为 3.5, 28, 430 nM)。

Marizomib(Synonyms: Salinosporamide A; NPI-0052)

Marizomib Chemical Structure

CAS No. : 437742-34-2

规格 价格 是否有货 数量
100 μg ￥1500 In-stock

* Please select Quantity before adding items.

生物活性

Marizomib (Salinosporamide A) is a second-generation, irreversible, brain-penetrant, pan-proteasome inhibitor. Marizomib inhibits the CT-L (β5), CT-T-laspase-like (C-L, β1) and trypsin-like (T-L, β2) activities of the 20S proteasome (IC50=3.5, 28, and 430 nM, respectively)[1][2][3].

IC50 & Target

IC50: 3.5 nM (CT-L), 28 nM (CT-T-laspase-like), 430 nM (trypsin-like)[1]
体外研究
(In Vitro)

Marizomib (Salinosporamide A) (0.1-10000 nM; 72 hours) effectively reduces survival of D-54 and U-251 cells in a dose-dependent manner. The IC50s are ∼52 nM for U-251 and ∼20 nM for D-54[1].
Marizomib (24 hours; 60 nM) induces apoptosis and caspase-3 activation in glioma cells[1].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Proliferation Assay[1]

Cell Line: U-251 and D-54 cells
Concentration: 0.1, 1, 10, 100, 1000, 10000 nM
Incubation Time: 72 hours
Result: Effectively reduced survival of D-54 and U-251 cells in a dose-dependent manner.

Apoptosis Analysis[1]

Cell Line: D-54 cells
Concentration: 60 nM
Incubation Time: 24 hours
Result: Induces D-54 cells apoptosis.

Western Blot Analysis[1]

Cell Line: D-54 cells
Concentration: 60 nM
Incubation Time: 24 hours
Result: Led to increased activity of caspase-3 in a dose-dependent manner.

体内研究
(In Vivo)

Marizomib (Salinosporamide A) (0.15 mg/kg; i.v; twice a week for three weeks) significantly decreases tumor growth, and is not associated with any toxicity[3].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: CB-17 SCID-male mice (4-6 weeks old)[3]
Dosage: 0.15 mg/kg
Administration: i.v; twice a week for three weeks
Result: Significantly decreased tumor growth, and was not associated with any toxicity.

Clinical Trial

分子量

313.78

Formula

C15H20ClNO4
CAS 号

437742-34-2
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
溶解性数据
In Vitro: 

DMSO : ≥ 100 mg/mL (318.69 mM)

* “≥” means soluble, but saturation unknown.

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 3.1869 mL 15.9347 mL 31.8695 mL
5 mM 0.6374 mL 3.1869 mL 6.3739 mL
10 mM 0.3187 mL 1.5935 mL 3.1869 mL

*

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用； 以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

  • 1.

    请依序添加每种溶剂： 10% DMSO    40% PEG300    5% Tween-80    45% saline

    Solubility: ≥ 2.08 mg/mL (6.63 mM); Clear solution

    此方案可获得 ≥ 2.08 mg/mL (6.63 mM，饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。

    将 0.9 g 氯化钠，完全溶解于 100 mL ddH₂O 中，得到澄清透明的生理盐水溶液

  • 2.

    请依序添加每种溶剂： 10% DMSO    90% corn oil

    Solubility: ≥ 2.08 mg/mL (6.63 mM); Clear solution

    此方案可获得 ≥ 2.08 mg/mL (6.63 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。

    以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。

*以上所有助溶剂都可在 上海金畔生物科技有限公司 网站选购。
参考文献

  • [1]. Di K, et al. Marizomib activity as a single agent in malignant gliomas: ability to cross the blood-brainbarrier. Neuro Oncol. 2016 Jun;18(6):840-8.

    [2]. Kale AJ, et al. Molecular mechanisms of acquired proteasome inhibitor resistance. J Med Chem. 2012 Dec 13;55(23):10317-27.

    [3]. Singh AV, et al. Pharmacodynamic and efficacy studies of the novel proteasome inhibitor NPI-0052 (marizomib) in a human plasmacytoma xenograft murine model. Br J Haematol. 2010 May;149(4):550-9.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务